AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00829582
Drug: ETI-204, Anthim
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single intravenous infusion of 120, 240 or 360 mg of ETI-204
Trial: NCT00041262
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01323660
Drug: GSK573719/GW642444 125/25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125mcg/ 25mcg QID (Once daily , inhaled)
Trial: NCT01323660
Drug: GSK573719/GW642444 62.5/25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 62.5mcg/25mcg QID
Trial: NCT01323660
Drug: GSK573719 125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125mcg QID
Trial: NCT03950882
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsule
Trial: NCT00002556
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02590263
Drug: ABT-414
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-414 will be administered by intravenous infusion
Trial: NCT03437278
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 0 mg per 1 ml liquid injection once every 4 weeks.
Trial: NCT01128738
Drug: GSK1358820
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Onabotulinum toxin type A
Trial: NCT01128738
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01995383
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral administrations
Trial: NCT01995383
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 single oral administrations
Trial: NCT01995383
Drug: RO6836191
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally administered, single ascending doses
Trial: NCT01995383
Drug: RO6836191
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 single oral doses
Trial: NCT01995383
Drug: RO6836191
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration
Trial: NCT00455325
Drug: Active Comparator: Second Intervention (3 weeks)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily 80mg chloroquine or placebo tablet 3 Weeks followed by euglycemic clamp procedure; 24 hour Ambulatory Blood Pressure; Oral Glucose tolerance Test; serum collection; 24 hour urine collection; collection of peripheral blood mononuclear cells
Trial: NCT00455325
Drug: Active Comparator: Third Intervention (3 weeks)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily 80mg tablet for 3 weeks followed by: euglycemic clamp procedure; 24 hour Ambulatory Blood Pressure; Oral Glucose tolerance Test; serum collection; 24 hour urine collection; collection of peripheral blood mononuclear cells
Trial: NCT00455325
Drug: Active Comparator: Fourth Intervention (3 weeks)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily 250mg tablet for 3 weeks followed by: euglycemic clamp procedure; 24 hour Ambulatory Blood Pressure; Oral Glucose tolerance Test; serum collection; 24 hour urine collection; collection of peripheral blood mononuclear cells
Trial: NCT00501631
Drug: Placebo for VIVITROL 380 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered via IM injection once every 4 weeks.
Trial: NCT00165139
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Described under detailed description
Trial: NCT00180687
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulised Normal Saline
Trial: NCT00490009
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As premedication 30 to 60 minutes before antibody infusion; 650 mg, oral. Used to as to relieve pain
Trial: NCT00051311
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Recipients will receive induction therapy with fludarabine, cyclophosphamide, etoposide, doxorubicin, vincristine, and prednisone. One cycle is 5 days on drug therapy followed by a 16 day rest period.
Trial: NCT01078675
Drug: rosuvastatin calcium
RxNorm normalized name: Rosuvastatin Calcium
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5 mg, oral, once daily, 24 months
Trial: NCT01078675
Drug: rosuvastatin calcium
RxNorm normalized name: Rosuvastatin Calcium
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10 mg, oral, once daily, 24 months
Trial: NCT01078675
Drug: rosuvastatin calcium
RxNorm normalized name: Rosuvastatin Calcium
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 20 mg, oral, once daily, 24 months
Trial: NCT00051311
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Recipients will receive induction therapy with fludarabine, cyclophosphamide, etoposide, doxorubicin, vincristine, and prednisone. One cycle is 5 days on drug therapy followed by a 16 day rest period.
Trial: NCT00051311
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Recipients will receive 4 doses of methotrexate by vein after the transplant to help prevent graft-versus-host disease (GVHD)..
Trial: NCT02159196
Drug: acetylcysteine and salbutamol
RxNorm normalized name: Acetylcysteine
DrugBank: Acetylcysteine magnesium (DB14080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: routine nebulisation of a 3 mL-solution of acetylcysteine (fluimucil 100mg/ml) and a 2.5 mL solution containing salbutamol (ventolin 2.5 Nebules 2.5mg/2.5 ml) four times daily
Trial: NCT03628079
Drug: ReposMBZ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules 50mg, 100mg, 200mg
Trial: NCT01543165
Drug: Ketorolac and nefopam balanced analgesia
RxNorm normalized name: nefopam
DrugBank: Nefopam (DB12293)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential intravenous administration of ketorolac and nefopam
Trial: NCT01543165
Drug: Balanced analgesia using ketorolac and morphine
RxNorm normalized name: phenylephrine and ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential intravenous administration of ketorolac and morphine
Trial: NCT01543165
Drug: Pain control with single analgesics (ketorolac)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This arm do not use balanced analgesia. Instead, ketorolac IV administration followed by 50cc normal saline administration (for blinding) will be used in this group.
Trial: NCT02683941
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline solution 0.9% administered via deep subcutaneous injection every 28 days until disease progression.
Trial: NCT02683941
Drug: Best Supportive Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Best Supportive Care is best available therapy at the choice of the investigator
Trial: NCT00761098
Drug: Standard Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Care: 25% salt poor albumin administered day 1 (1.5g/kg) and day 3 (1.0g/kg)
Trial: NCT00761098
Drug: Experimental
RxNorm normalized name: WA-001 Experimental Soil Surfactant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25% Salt Poor Albumin administered per standard care on day 1 (1.5g/kg). Second dose administered on day 2 only to those individuals with renal insufficiency and risk for renal failure.
Trial: NCT01868568
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose administered subcutaneously (s.c., under the skin).
Trial: NCT00587665
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline given of equal volume to drug
Trial: NCT03703895
Drug: Topical AFX5931
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active Comparator, Topical AFX5931, a medication combining a small, potent anti-inflammatory molecule.
Trial: NCT03861377
Drug: Remifentanil R2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0,7 microg/kg
Trial: NCT03861377
Drug: Remifentanil R4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,1 microg/kg
Trial: NCT03861377
Drug: Remifentanil R8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,7 microg/kg
Trial: NCT03703895
Drug: Topical Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Comparator, Topical Placebo.
Trial: NCT00102609
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin 50 to 75 mg/m2 administered intravenously on Day 1
Trial: NCT03908242
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: salvianolic acid A/Placebo 90 mg bid; salvianolic acid A/Placebo 180 mg qd
Trial: NCT00714233
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo to the active metformin arm. 2 capsules BID x 24 weeks.
Trial: NCT02730962
Drug: Clindamycin
RxNorm normalized name: Clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clindamycin 3 times a day for 5 days
Trial: NCT01272804
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match PF-04937319 will be provided. Subjects will be dosed for 14 days. In each cohort 9 subjects will receive PF-04937319 and 3 will receive placebo.
Trial: NCT01894958
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strawberry flavored solution
Trial: NCT00856180
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00984867
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablet
Trial: NCT04876534
Drug: MethylPREDNISolone Injectable Solution
RxNorm normalized name: methylprednisolone Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration
Trial: NCT02900716
Drug: DTRMWXHS-12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTRMWXHS-12
Trial: NCT02900716
Drug: DTRM-505
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTRMWXHS-12 and everolimus
Trial: NCT02900716
Drug: DTRM-555
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTRMWXHS-12 and everolimus and pomalidomide
Trial: NCT01145144
Drug: dehydroepiandrosterone crystalline fine powder
RxNorm normalized name: Mesembryanthemum crystallinum whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01668797
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo comparator for 52 weeks
Trial: NCT00406653
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline, IV, 0 mg/kg, every 28 days.~Induction Period 3 months~Maintenance Period 12 months
Trial: NCT01257165
Drug: Ethanol
RxNorm normalized name: Ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg per 70 kg body weight, given orally as a single dose
Trial: NCT01257165
Drug: Placebo pill
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pill identical to zopiclone pill, given orally as a single dose
Trial: NCT01257165
Drug: Placebo drink
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo drink, given orally as a single dose
Trial: NCT04865562
Drug: 0.5% cholorbutanol, saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 mg 0.5% cholorbutanol, 50mg saline
Trial: NCT00483262
Drug: CCI-779
RxNorm normalized name: dengue virus live antigen, CYD serotype 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given by injection once a week for 5 weeks (5 weeks equals one cycle) for up to 8 cycles
Trial: NCT00558753
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for Given 2 hours prior to surgery, and twice a day for 14 postoperative days.
Trial: NCT00377598
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-583 placebo-matching tablets, orally, once daily for up to 8 weeks
Trial: NCT01118611
Drug: Aurora B/C kinase inhibitor GSK1070916A
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01794923
Drug: IBU BID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-cm strip of IBU 5% topical gel applied to the affected area BID (twice daily) x 3 days
Trial: NCT01794923
Drug: Placebo BID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-cm strip of placebo topical gel applied to the affected area BID (twice daily) x 3 days
Trial: NCT01794923
Drug: Placebo TID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-cm strip of placebo topical gel applied to the affected area TID (three times daily) x 3 days
Trial: NCT00487721
Drug: Silibin-Phytosome
RxNorm normalized name: silybin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will take Silibin-Phytosome for 2-10 weeks. The dose of Silibin-Phytosome is 13 grams daily, in three divided doses. Patients will be asked to mix 1 level teaspoon and 1 heaping ¼ teaspoon of Silybin-Phytosome powder into 6 tablespoons of applesauce for each dose.
Trial: NCT00918190
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline
Trial: NCT00530777
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral placebo twice daily from 34 weeks gestation to 1 year postpartum
Trial: NCT01210079
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo titrated over 1 week with established dose taken daily for 5 weeks.
Trial: NCT04296240
Drug: Oxaliplatin and capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients receive 5-Fu and oxaliplatin based neoadjuvant chemotherapy for 3 months
Trial: NCT00106145
Drug: Comparator: MK0752, Notch Inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose escalating beginning with rising dose levels of 300, 450, and 600 mg/day in a continuous dosing schedule.
Trial: NCT00106145
Drug: Comparator: MK0752, Notch Inhibitor - 450 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose 450 mg capsules daily for 28 day cycles.
Trial: NCT00106145
Drug: Comparator: MK0752, Notch Inhibitor - 3 days on, 4 off
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose escalating in a repeating intermittent dosing schedule of 3 days on and 4 days off at rising dose levels of 450, 600, 800, 1000, 1200, and 1400 mg/day.
Trial: NCT00106145
Drug: Comparator: MK0752, Notch Inhibitor - 1 day on, 6 off
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose escalating in a repeating intermittent dosing schedule of 1 day on/6 days off at rising dose levels of 600, 900, 1200, 1500, 1800, 2400, 3200 mg/day once weekly and then increase at 33% increments.
Trial: NCT01513356
Drug: BKM120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BKM120 will be administered on a continuous once daily dosing schedule at a dose of 100 mg (p.o.)until progression of disease or unacceptable toxicity or a maximum of 4 weeks.
Trial: NCT00106145
Drug: Comparator: MK0752, Notch Inhibitor - 3 days on, 4 off 350 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose 350 mg capsules daily intermittent 3 days on/4 days off dosing. THIS DOSING SCHEDULE IS NO LONGER UNDER INVESTIGATION
Trial: NCT00182403
Drug: UFH 250 U/kg or LMWH 100 U/kg sc twice daily
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02668185
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01013597
Drug: LBH589
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LBH589 20mg by mouth three times weekly (Monday/Wednesday/Friday) for 28-day cycles.
Trial: NCT01110941
Drug: S-1, leucovorin, oxaliplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1(20mg、25mg), capsule, 40\~60mg, Bid,p.o., day1\~7； LV (25 mg), tablet, 25mg,Bid,p.o., day1\~7； L-OHP (50 mg),injection 85mg/m2, day1. repeated at every 2 weeks cycle till disease progression.
Trial: NCT00626639
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by intravenous (IV) bolus injection
Trial: NCT02525068
Drug: AZD5363
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Until confirmed disease progression.
Trial: NCT04780321
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 patients receipt placebo intravenous infusion on day 1
Trial: NCT02387086
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03253926
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule BID
Trial: NCT01602523
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo inhaler once daily 28 days
Trial: NCT01438684
Drug: RPh201
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 microliter s.c. twice a week for 3 months
Trial: NCT00434434
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous repeating dose
Trial: NCT02463643
Drug: Z-215 10mg
RxNorm normalized name: zinc pyrithione 10 MG/ML [Theraplex Z]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Z-215 10mg, capsules
Trial: NCT02463643
Drug: Z-215 20mg
RxNorm normalized name: erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Z-215 20mg, capsules
Trial: NCT00687700
Drug: GSK961081
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK961081 multidose dry powder inhaler (Diskus inhaler) will be available with dosing strengths of 400 micrograms and 1200 micrograms administered once daily in the morning.
Trial: NCT00687700
Drug: GSK961081 matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK961081 matching placebo multidose dry powder inhaler (Diskus inhaler) will be available to be administered once daily in the morning.
Trial: NCT02463643
Drug: Z-215 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Z-215 placebo-matching capsules
Trial: NCT04005053
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02544217
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01637623
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule daily for 6 weeks
Trial: NCT03883386
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered via capsule
Trial: NCT04386343
Drug: CH1701 for prevention and treatment of radiation burns.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ch1701 is used for cancer patients who are treated with radiotherapy, then assess the safety and treatment effectiveness of the product.
Trial: NCT04386343
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo was used on patients as a control for the doses of CH1701
Trial: NCT02327039
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tables of Dapagliflozin placebo
Trial: NCT02404571
Drug: GDP chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gemcitabine (1000mg/m2 intravenously over 30 minutes on days 1 and 8), cisplatin (25mg/m2 intravenously over 60 minutes on days 1-3), and dexamethasone (20mg/d orally on days 1-4 and days 11-14), which was administered every 21 days.
Trial: NCT00964782
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient will receive a look-alike placebo. Enrolled patients will be randomized to receive Placebo first and then crossed over to receive the opposite intervention, Sildenafil.
Trial: NCT00964782
Drug: Placebo 2
RxNorm normalized name: Ethinyl Estradiol/Norethindrone Acetate;Placebo 20 MCG-1 MG; NA Oral Tablet, Disintegrating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient will receive a look-alike placebo. Enrolled patients will receive Placebo, the crossed over intervention from their initial intervention (Sildenafil).
Trial: NCT03879837
Drug: Placebo pressurized metered dose inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: no active content
Trial: NCT04156698
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine is a chemotherapy drug.
Trial: NCT02767401
Drug: aspirin, clopidogrel, ticagrelor, atorvastatin, rosuvastatin, betaloc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal medical therapy includes dual antiplatelet therapy and statins (aspirin, clopidogrel, ticagrelor, atorvastatin, rosuvastatin, betaloc). And optimal medical therapy should include adequate ventricular rate-limiting medication (i.e. Beta-blocker or rate-limiting calcium antagonist) where appropriate. Anti-anginal therapy should be used if the patients have symptom.
Trial: NCT03084861
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. Artificial tears: Lubristil ®~2. Therapeutic Contact lens: Air Optix Night\&Day
Trial: NCT05081687
Drug: Folfirinox
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-FU 2400mg/m2; Oxaliplatin 85 mg/m2, Irinotecan 150mg/m2
Trial: NCT01244100
Drug: PL2200 fed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fed state
Trial: NCT02629770
Drug: usual antibiotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pharmacological studies in patients treated with usual antibiotics, for different types of joint and bone infections
Trial: NCT00163059
Drug: NMDA Antagonist, CP-101,606 (traxoprodil)
FDA approved: no
EMA approved: no
PMDA approved: no